Kyowa Kirin looks for safety and efficacy benefits as it takes novel antithrombin to Phase III
This article was originally published in Scrip
Executive Summary
Kyowa Hakko Kirin has begun a Japanese Phase III clinical trial with what it says is the first recombinant human antithrombin product engineered to be deficient in fucose, providing potential advantages over both the natural blood plasma-derived glycoprotein and other synthetic versions.